Drug Trial Radar · NCT07735767
Tdap Vaccination During Pregnancy or Postpartum and Lactation-Related Outcomes
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36,245
Actual
Start
Jan 2014
Primary completion
Dec 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- HealthPartners InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi; Kaiser Permanente
- First posted
- Jul 30, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 16 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A retrospective cohort study based on the secondary use of pre-existing data. The study assesses the association between antenatal and postpartum maternal Tdap vaccination and select infant and lactation-related outcomes.
Conditions
- Pertussis Vaccines
Interventions
Tetanus Toxoid, acellular pertussis, diphtheria toxoidBiological
No investigational vaccines will be administered in this study. Participants will be included in the study on the basis of their having received Tdap vaccine as part of routine care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Infant growth - failure to thrive (Subgroup Pregnancy)Time frame: 3 months (91 days) to 12 months of age
- Infant growth - failure to thrive (Subgroup Postpartum)Time frame: 3 months (91 days) to 12 months of age
- Infant health care utilization - Number of infant outpatient visits up to 6 months of age (Subgroup Pregnancy)Time frame: 0 to 6 months after delivery
- Infant health care utilization - Number of infant outpatient visits in the 90 days after index date (Subgroup Postpartum )Time frame: up to 6 months: 90-day window for vaccination plus 90-day window for outcome assessment
- Infant health care utilization - Number of infant emergency department visits up to 6 months of age (Subgroup Pregnancy)Time frame: 0 to 6 months after delivery
- Infant health care utilization - Number of infant emergency department visits in 90 days after index date (Subgroup Postpartum)Time frame: Up to 6 months: 90-day window for vaccination plus 90-day window for outcome assessment.
- Human milk feeding initiation vs no initiation (Subgroup Pregnancy)Time frame: 0 to 12 months
- Any human milk feeding vs none around the 2-month Well Child Visit (WCV) (Subgroup Pregnancy)Time frame: 42 to 104 days after delivery
- Any human milk feeding vs none around the 2-month WCV (Subgroup Postpartum)Time frame: 42 to 104 days after delivery
- Exclusive human milk feeding vs none around the 2-month WCV (Subgroup Pregnancy)Time frame: 42 to 104 days after delivery
- Exclusive human milk feeding vs none around the 2-month WCV (Subgroup Postpartum)Time frame: 42 to 104 days after delivery
- Any human milk feeding vs none around the 6-month WCV (Subgroup Pregnancy)Time frame: 148 to 210 days after delivery
- Any human milk feeding vs none around the 6-month WCV (Subgroup Postpartum)Time frame: 148 to 210 days after delivery
- Exclusive human milk feeding vs none around the 6-month WCV (Subgroup Pregnancy)Time frame: 148 to 210 days after delivery
- Exclusive human milk feeding vs none around the 6-month WCV (Subgroup Postpartum)Time frame: 148 to 210 days after delivery
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.